Download PDF
Zentralbl Chir 2012; 137(6): 522-526
DOI: 10.1055/s-0031-1283917
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Extrahepatische Gallenwegstumoren: aktueller Stand der palliativen Therapie

Extrahepatic Cholangiocarcinoma: Current State of Palliation Therapy
G. W. Wolkersdörfer
1   Paracelsus Medizinische Privatuniversität, Universitätsklinik für Innere Medizin I, Salzburg, Österreich
,
F. Berr
1   Paracelsus Medizinische Privatuniversität, Universitätsklinik für Innere Medizin I, Salzburg, Österreich
,
C. Nawara
2   Paracelsus Medizinische Privatuniversität, Universitätsklinik für Chirurgie, Salzburg, Österreich
,
K. Emmanuel
3   Krankenhaus der Barmherzigen Schwestern, Abteilung für Allgemein- und Viszeralchirurgie, Linz, Österreich
› Author Affiliations
Further Information

Publication History

Publication Date:
17 April 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Einleitung: Die Dekompression der Gallenwege ist vorrangiges Therapieziel in der palliativen Situation, weil so infektiöse Komplikationen und die sekundäre billiäre Zirrhose verhindert sowie die Lebensqualität besser erhalten werden können.

Kernaussagen: Derzeit scheint in der palliativen Situation die photodynamische Therapie mit Einlage von Endoprothesen am besten belegt zu sein.

Methode: Selektive Literaturübersicht kombiniert mit eigenen klinischen Erfahrungen.

Schlussfolgerung: Die therapeutischen Mittel sollten sich ferner der Ausbreitung und dem Stadium anpassen: Bei lokal fortgeschrittener oder progredienter Erkrankung (Stadium III) ein lokal-ablatives Verfahren, bei systemischem Progress (Stadium IV) die systemische Chemotherapie.

Abstract

Introduction: Decompression of bile ducts is the priority objective in the non-curative stage of hilar cholangiocarcinoma. Only this will prevent or slow down infectious complications and secondary biliary cirrhosis thereby sustaining the quality of life.

Key Statements: At present, photodynamic therapy combined with insertion of an endoprosthesis seems to be best documented and most appropriate therapy.

Methods: Data from a selective literature search combined with our clinical experience were evaluated.

Conclusions: Therapeutic measures should match the dissemination and stage of the tumor: in locally advanced or progressing disease (stage III) a local ablating therapy, in systemically progressing disease (stage IV) systemic chemotherapy should be utilised.

Schlüsselwörter

Gallenwegstumor - Klatskin Tumor - palliative Therapie - photodynamische Therapie

Key words

Cholangiocarcinoma - Klatskin tumour - palliation therapy - photodynamic therapy
 

  • Literatur

  • 1 Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667
    CrossrefPubMedGoogle Scholar
  • 2 Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314
    CrossrefPubMedGoogle Scholar
  • 3 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184
    Google Scholar
  • 4 Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70: 1498-1501
    CrossrefPubMedGoogle Scholar
  • 5 Kimura W, Nagai H, Atomi Y et al. Clinicopathological characteristics of hepatic hilar bile duct carcinoma. Hepatogastroenterology 1993; 40: 21-27
    PubMedGoogle Scholar
  • 6 de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378
    CrossrefPubMedGoogle Scholar
  • 7 Smith AC, Dowsett JF, Russell RC et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
    CrossrefPubMedGoogle Scholar
  • 8 Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl. 06) VI1-9
    CrossrefPubMedGoogle Scholar
  • 9 Bowling TE, Galbraith SM, Hatfield AR et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996; 39: 852-855
    CrossrefPubMedGoogle Scholar
  • 10 Kamada T, Saitou H, Takamura A et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and / or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34: 767-774
    CrossrefPubMedGoogle Scholar
  • 11 Valek V, Kysela P, Kala Z et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007; 62: 175-179
    CrossrefPubMedGoogle Scholar
  • 12 Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-387
    CrossrefPubMedGoogle Scholar
  • 13 Triesscheijn M, Baas P, Schellens JH et al. Photodynamic therapy in oncology. Oncologist 2006; 11: 1034-1044
    CrossrefPubMedGoogle Scholar
  • 14 Berr F. Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 2004; 24: 177-187
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Chahal P, Baron TH. Endoscopic palliation of cholangiocarcinoma. Curr Opin Gastroenterol 2006; 22: 551-560
    CrossrefPubMedGoogle Scholar
  • 16 Ayaru L, Bown SG, Pereira SP. Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 2005; 35: 1-13
    CrossrefPubMedGoogle Scholar
  • 17 Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol 2004; 18: 147-154
    CrossrefPubMedGoogle Scholar
  • 18 Dumoulin FL, Horst E, Sauerbruch T et al. [Palliative locoregional therapy for hilar cholangiocarcinoma: photodynamic therapy and brachytherapy]. Zentralbl Chir 2007; 132: 336-341
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Fayter D, Corbett M, Heirs M et al. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess 2010; 14: 1-288
    PubMedGoogle Scholar
  • 20 Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363
    CrossrefPubMedGoogle Scholar
  • 21 Zoepf T, Jakobs R, Arnold JC et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
    CrossrefPubMedGoogle Scholar
  • 22 Witzigmann H, Berr F, Ringel U et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1 / r2 resection. Ann Surg 2006; 244: 230-239
    CrossrefPubMedGoogle Scholar
  • 23 Berr F, Tannapfel A, Lamesch P et al. Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J Hepatol 2000; 32: 352-357
    CrossrefPubMedGoogle Scholar
  • 24 Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003; 97: 2783-2790
    CrossrefPubMedGoogle Scholar
  • 25 Dechene A, Hildgard P, Maldonado-Lopez EJ et al. Survival difference in patients with photodynamic therapy of nonresectable bile duct cancer using different hematoporphyrins. Gastrointest Endosc 2007; 65: A227-A227
    PubMedGoogle Scholar
  • 26 Bown SG, Rogowska AZ, Whitelaw DE et al. Photodynamic therapy for cancer of the pancreas. Gut 2002; 50: 549-557
    CrossrefPubMedGoogle Scholar
  • 27 Neureiter D, Emmanuel K, Kiesslich T et al. POSTER: Pilotprojekt – Photodynamische Therapie inoperabler Gallengangskarzinome mit Temoporfin. In: 13. AGO-WINTERKURS: Onkogenese und Molekulare Therapie Gastrointestinaler Tumoren. Salzburg, Austria: 2007
    PubMedGoogle Scholar
  • 28 Brunner TB, Schwab D, Meyer T et al. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 2004; 180: 751-757
    CrossrefPubMedGoogle Scholar
  • 29 Deodato F, Clemente G, Mattiucci GC et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006; 64: 483-488
    CrossrefPubMedGoogle Scholar
  • 30 Momm F, Schubert E, Henne K et al. Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother Oncol 2010; 95: 99-102
    CrossrefPubMedGoogle Scholar
  • 31 Polistina FA, Guglielmi R, Baiocchi C et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 2011; 99: 120-123
    CrossrefPubMedGoogle Scholar
  • 32 Leong E, Chen WW, Ng E et al. Outcomes from Combined Chemoradiotherapy in Unresectable and Locally Advanced Resected Cholangiocarcinoma. J Gastrointest Cancer 2010; DOI: 10.1007/s12029-010-9213-5.
    PubMedGoogle Scholar
  • 33 Kopek N, Holt MI, Hansen AT et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94: 47-52
    CrossrefPubMedGoogle Scholar
  • 34 Yamashita Y, Taketomi A, Itoh S et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Jpn J Clin Oncol 2010; 40: 24-28
    CrossrefPubMedGoogle Scholar
  • 35 Knox JJ, Hedley D, Oza A et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338
    CrossrefPubMedGoogle Scholar
  • 36 Park BK, Kim YJ, Park JY et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 2006; 21: 999-1003
    CrossrefPubMedGoogle Scholar
  • 37 Okusaka T, Ishii H, Funakoshi A et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647-653
    CrossrefPubMedGoogle Scholar
  • 38 Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902
    CrossrefPubMedGoogle Scholar
  • 39 Andre T, Reyes-Vidal JM, Fartoux L et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99: 862-867
    CrossrefPubMedGoogle Scholar
  • 40 Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281
    Google Scholar
  • 41 Lee J, Park SH, Chang HM et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; DOI: 10.1016/S1470-2045(11)70301-1.
    PubMedGoogle Scholar
  • 42 Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654
    CrossrefPubMedGoogle Scholar
  • 43 Okusaka T, Nakachi K, Fukutomi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474
    CrossrefPubMedGoogle Scholar
  • 44 Kahaleh M, Mishra R, Shami VM et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6: 290-297
    CrossrefPubMedGoogle Scholar
  • 45 Schiefke I, Zabel-Langhennig A, Wiedmann M et al. Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc 2003; 58: 213-219
    CrossrefPubMedGoogle Scholar